As it finishes up a pivotal study to support an application to the U.S. Food and Drug Administration for marketing clearance of its first product, medical device company AxioMed Spine Corp. has brought in $3.6 million in fresh capital. The Cleveland-area company develops products focused on restoring spinal function in patients with degenerative spine disease. […]
Fresh off receiving the CE Mark for its cervical spinal disc replacement device, AxioMed Spine has added $5 million to its series D round of investment. The latest funding tranche brings Cleveland-area AxioMed’s series D round to $20 million, chief financial officer Jerry Baty said. European regulatory approval for AxioMed’s cervical disc complements the CE […]
In a webinar on April 16 at 1pm ET, Aneesh Chopra will moderate a discussion with executives from DocuSign, Velatura, and behavioral health providers on eConsent, health information exchange and compliance with the CMS Final Rule on interoperability.
Medical device developer AxioMed Spine has received European regulatory approval to market its cervical spinal disc replacement device. The CE Mark for AxioMed’s Freedom cervical disc complements the earlier European regulatory approval for the company’s Freedom lumbar spinal disc replacement, according to a statement from the Cleveland-area company. AxioMed is currently selling the lumbar disc […]
A $500,000 loan from the state of Ohio will help AxioMed Spine manufacture and launch the company's second product, an artificial cervical spine disc.
AxioMed Spine Corp. has raised $14.5 million in Series D funding to help the Garfield Heights, Ohio company finish enrolling patients for a pivotal U.S. clinical study of its lumbar disc replacement, as well as earn CE Mark approval for its cervical disc and start sales in Europe. The developer of next-generation spinal disc replacements […]
Updated 4:36 p.m. Cleveland Clinic Innovations — the corporate venturing arm of the nation’s top heart hospital — is entering its second decade with a first-of-its-kind venture ranking, a brand-new incubator building and a growing portfolio of spin-out companies. Perhaps most impressive, those companies — 33 in all — have attracted more than $340 million […]
A specialty drug is a class of prescription medications used to treat complex, chronic or rare medical conditions. Although this classification was originally intended to define the treatment of rare, also termed “orphan” diseases, affecting fewer than 200,000 people in the US, more recently, specialty drugs have emerged as the cornerstone of treatment for chronic and complex diseases such as cancer, autoimmune conditions, diabetes, hepatitis C, and HIV/AIDS.
MedCity News President Chris Seper appeared on air of content partner WKYC-TV, discussing three Cleveland-area medical device companies: AxioMed Spine, CerviLenz and Neuros Medical.
AxioMed Spine Corp. has completed the first part of its third round of financing, raising $6.4 million from "leading venture capital firms" on its way to a $18.5 million goal.
AxioMed Spine Corp. said Tuesday it has received Europe's CE Marking -- much like Food and Drug Administration market clearance in the United States -- to introduce its disc replacement for the lower spine to the 27 countries that belong to the European Union. It's the first market clearance for Freedom -- one of a small group of next-generation spinal disc replacements designed to function more like the natural spine.